308 related articles for article (PubMed ID: 25053403)
1. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
Glorie L; Behets GJ; Baerts L; De Meester I; D'Haese PC; Verhulst A
Am J Physiol Endocrinol Metab; 2014 Sep; 307(5):E447-55. PubMed ID: 25053403
[TBL] [Abstract][Full Text] [Related]
2. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes.
Connelly KA; Zhang Y; Advani A; Advani SL; Thai K; Yuen DA; Gilbert RE
Cardiovasc Ther; 2013 Oct; 31(5):259-67. PubMed ID: 22963483
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of proline-containing dipeptide noopept and inhibitor of dipeptidyl peptidase-4 sitagliptin in a rat model of developing diabetes.
Ostrovskaya RU; Ozerova IV; Gudascheva TA; Kapitsa IG; Ivanova EA; Voronina TA; Seredenin SB
Bull Exp Biol Med; 2014 Jan; 156(3):342-6. PubMed ID: 24771372
[TBL] [Abstract][Full Text] [Related]
5. Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin.
Lu YL; Zhou DQ; Zhai HL; Wu H; Guo ZK
Chin Med J (Engl); 2012 May; 125(10):1690-4. PubMed ID: 22800885
[TBL] [Abstract][Full Text] [Related]
6. Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats.
Hou J; Zheng D; Fan K; Yu B; Xiao W; Ma J; Jin W; Tan Y; Wu J
Pharmacology; 2012; 90(3-4):177-82. PubMed ID: 22948814
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.
Nishioka T; Shinohara M; Tanimoto N; Kumagai C; Hashimoto K
Dermatology; 2012; 224(1):20-1. PubMed ID: 22056790
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.
Maiztegui B; Borelli MI; Madrid VG; Del Zotto H; Raschia MA; Francini F; Massa ML; Flores LE; Rebolledo OR; Gagliardino JJ
Clin Sci (Lond); 2011 Jan; 120(2):73-80. PubMed ID: 20795946
[TBL] [Abstract][Full Text] [Related]
9. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
Perusicová J
Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats.
Pintana H; Apaijai N; Chattipakorn N; Chattipakorn SC
J Endocrinol; 2013 Jul; 218(1):1-11. PubMed ID: 23591914
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
[TBL] [Abstract][Full Text] [Related]
14. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
17. Amylin and bone metabolism in streptozotocin-induced diabetic rats.
Horcajada-Molteni MN; Chanteranne B; Lebecque P; Davicco MJ; Coxam V; Young A; Barlet JP
J Bone Miner Res; 2001 May; 16(5):958-65. PubMed ID: 11341342
[TBL] [Abstract][Full Text] [Related]
18. Effects of DPP-4 inhibition on cardiac metabolism and function in mice.
Lenski M; Kazakov A; Marx N; Böhm M; Laufs U
J Mol Cell Cardiol; 2011 Dec; 51(6):906-18. PubMed ID: 21871459
[TBL] [Abstract][Full Text] [Related]
19. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
[TBL] [Abstract][Full Text] [Related]
20. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Satoh-Asahara N; Sasaki Y; Wada H; Tochiya M; Iguchi A; Nakagawachi R; Odori S; Kono S; Hasegawa K; Shimatsu A
Metabolism; 2013 Mar; 62(3):347-51. PubMed ID: 23062489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
